Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Domvanalimab + Zimberelimab With Carboplatin and Paclitaxel in First-line Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
2024-513121-22-00Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Dec 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 11
01
Overview
Phase 2, randomised trial of domvanalimab, zimberelimab, carboplatin and paclitaxel in head and neck squamous cell carcinoma (HNSCC), sponsored by Gilead Sciences. Started Dec 2024; status: completed.
02
Drugs
domvanalimabzimberelimabcarboplatinpaclitaxel
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2024-513121-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513121-22-00.